A Phase 2 Study of Epcoritamab in People With B-Cell Lymphoma Who Received CAR T-Cell Therapy

Full Title

Multicenter, Randomized Phase II Study of Epcoritamab for Patients with Aggressive B-cell Lymphomas Achieving a Partial Response After CD19-Directed CAR-T Therapy

Purpose

Researchers want to see if epcoritamab works well in people with B-cell lymphoma. The people in this study have B-cell lymphoma that is not in complete remission after CAR T-cell therapy.

Normally when people have B-cell lymphoma that is not in complete remission, they do not immediately have another treatment. They have observation. That means their doctor closely monitors their disease with imaging tests to see if their disease is improving or worsening. If their disease gets worse, they may receive more treatment.

If you join this study, you will be randomly assigned to get epcoritamab or to be observed. Epcoritamab is a type of drug called a bispecific antibody. It is designed to attach to two different proteins at one time. Epcoritamab binds to CD20, a protein on the surface of cancer cells. It also attaches to another protein called CD3, which is found on the surface of immune cells called T cells. When epcoritamab attaches to CD3 and CD20 at the same time, it activates T cells to kill cancer cells. It is given as a subcutaneous (under the skin) injection.

Who Can Join

To join this study, there are a few conditions. You must:

• Have had CAR T-cell therapy for B-cell lymphoma and not be in complete remission, based on a PET scan performed 1 month after CAR T-cell treatment.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Miguel-Angel Perales’ office at 646-608-3757.